The elevation of FGF21 by long-acting FGF21 analogs shows significant improvements in dyslipidemia and hepatic fat fractions in nonalcoholic steatohepatitis patients (7, 8). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.